Legend Biotech (LEGN) Operating Leases (2019 - 2026)
Legend Biotech's (LEGN) quarterly Operating Leases came in at $112.1 million in Q1 2026, up 116.73% YoY from $51.7 million in Q1 2025, and up 28.56% on a QoQ basis from $87.2 million in Q4 2025.
Legend Biotech (LEGN) Operating Leases (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Operating Leases data on file, last reported at $112.1 million in Q1 2026.
- Quarterly Operating Leases rose 116.73% year-over-year to $112.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.1 million (up 116.73% YoY) and the FY2025 annual result came in at $87.2 million, up 95.52% from the prior year.
- Operating Leases grew to $112.1 million in Q1 2026, from $87.2 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $112.1 million in Q1 2026 to a low of $23.6 million in Q4 2022.
- A 5-year average of $56.3 million and a median of $44.9 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases surged 842.57% — and 2024, when it dropped 0.9%.
- Tracing LEGN's Operating Leases over 5 years: stood at $23.6 million in 2022, then soared by 87.14% to $44.2 million in 2023, then gained by 0.98% to $44.6 million in 2024, then surged by 95.52% to $87.2 million in 2025, then rose by 28.56% to $112.1 million in 2026.
- The last three Operating Leases figures came in at $112.1 million (Q1 2026), $87.2 million (Q4 2025), and $88.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.00 Mn |
| Mar 31, 2026 | 112.10 Mn |
| Dec 31, 2025 | 87.20 Mn |
| Sep 30, 2025 | 88.06 Mn |
| Jun 30, 2025 | 71.74 Mn |
| Mar 31, 2025 | 51.72 Mn |
| Dec 31, 2024 | 44.60 Mn |
| Sep 30, 2024 | 45.63 Mn |
| Jun 30, 2024 | 44.04 Mn |
| Mar 31, 2024 | 45.17 Mn |
| Dec 31, 2023 | 44.17 Mn |
| Sep 30, 2023 | 41.69 Mn |
| Jun 30, 2023 | 44.44 Mn |
| Mar 31, 2023 | 44.30 Mn |
| Dec 31, 2022 | 23.60 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Jun 30, 2021 | 1.62 Mn |
| Dec 31, 2020 | 3.37 Mn |
| Dec 31, 2019 | 5.06 Mn |